(d)

Exhibits

.

4.1*

Form of Warrant, to be issued by PLx Pharma Inc. to the Investors on June 14, 2017.

5.1*

Opinion of Jackson Walker L.L.P.

10.1

Amended and Restated Patent License Agreement, dated December 11, 2009

10.

2

Amendment No. 1 to Amended and Restated Patent License Agreement, dated April 15, 2011

10.3

*

Amendment No. 2 to Amended and Restated Patent License Agreement, dated December 17, 20 11

23.1*

Consent of Jackson Walker L.L.P. (included in Exhibit 5.1)

99.1*

Press Release, issued by PLx Pharma Inc. on June 12, 2017

99.2*

Placement Agency Agreement, dated as of June 9, 2017, by and between PLx Pharma Inc. and Raymond James & Associates, Inc.

99.3*

Form of Securities Purchase Agreement

* Filed as exhibit to Original Form 8-K filed with the

Securities and Exchange Commission on June 12, 2017

Confidential treatment requested.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly

caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLx

Pharma Inc.

By:

/s/

Natasha Giordano

Natasha Giordano

Title:

President and Chief Executive Officer

Dated:

August 15

, 2017

makes a similar move, sign up!

Other recent filings from the company include the following:

General statement of acquisition of beneficial ownership - Nov. 20, 2017
Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017

Auto Refresh

Feedback